Cardiol Therapeutics Inc Class A is experiencing a notable decline in its stock price, raising concerns among investors.
Cardiol Therapeutics Inc Class A (CRDL.TO) is facing challenges in today’s trading session, with its stock price dropping by 1.04% to CA$1.91. This decline comes despite recent positive developments regarding its clinical trials and capital raises, which have not translated into investor confidence.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$234.52M
52W high
$3.23
52W low
$1.23
1W change
-19.25%
Beta
0.72
Analyst Price Targets
Based on analyst covering CRDL · as of Sep 17, 2026
Wall Street analysts forecast CRDL stock price to rise 354.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+354.5% Upside
Current Price
C$1.32
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
76.8%
Annualized
90-Day Vol
66.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.31
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.05 | C$1.57 – C$2.67 |
| 60 trading days | C$2.17 | C$1.49 – C$3.16 |
| 90 trading days | C$2.31 | C$1.46 – C$3.65 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious as Cardiol Therapeutics struggles to maintain momentum despite achieving significant milestones in its clinical trials.
Stock Down 1.04% Today
Cardiol Therapeutics' market cap currently stands at CA$234.52 million, reflecting investor apprehension despite recent achievements.
Bull case
The company recently reached its Phase III MAVERIC trial enrollment target ahead of schedule, which could signal promising future prospects for its CardiolRx™ treatment.
Bear case
Even with this positive news, the stock's decline suggests that investor sentiment may be wavering. This could be due to broader market conditions or concerns about the company's ability to turn trial success into commercial viability.
Recent Developments
Advertisement
Cardiol Therapeutics has made significant strides, including hitting its enrollment target for the Phase III MAVERIC trial ahead of schedule. This trial aims to assess how effective CardiolRx™ is in treating recurrent pericarditis. However, despite these accomplishments, the stock is struggling to gain upward momentum.
Market Sentiment
The 1.04% drop in Cardiol's stock price today may reflect broader market trends or investor skepticism about the company's ability to leverage its recent successes. With a market cap of CA$234.52 million, the stock's performance is under scrutiny as investors weigh potential risks against the backdrop of its ongoing clinical trials.
Looking Ahead
As Cardiol Therapeutics continues with its clinical trials and works to improve its cash runway, investors will closely watch the company's ability to turn its research achievements into real results. The upcoming data readout from the MAVERIC trial will be crucial in shaping investor sentiment and stock performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
